The European Medicines Agency announced on Tuesday the launch of a "continuous review" procedure for the Chinese Sinovac vaccine against Covid-19, which paves the way for a possible request for an upcoming authorization in the European Union .

The decision of the Committee for Medicinal Products for Human Use of the EMA "to start the continuous review is based on preliminary results of laboratory studies (non-clinical data) and clinical studies", explains in a press release the European regulator based in Amsterdam.

  • Covid 19

  • Vaccine

  • China

  • Vaccination

  • Coronavirus

  • World